[Click eStock] "Boryung Pharmaceutical, Expectation to Reflect Value of Immune Cell Therapy"

[Asia Economy Reporter Hyungsoo Park] Hanyang Securities analyzed on the 3rd that the value of the cell therapy under development by Boryung Pharmaceutical has been under-reflected in the stock price.

Boryung Pharmaceutical's subsidiary, 'VigenCell,' is developing immune cell therapies. VigenCell is conducting a Phase 2 clinical trial of the NK/T lymphoma treatment 'VT-EBV-N.' A Phase 1 clinical trial of the acute myeloid leukemia treatment (VT-Tri-A) is also underway.

Byungyong Oh, a researcher at Hanyang Securities, explained, "The results of past clinical trials were excellent," adding, "In the investigator-initiated Phase 1 clinical trial of VT-EBV-N targeting 10 NK/T lymphoma patients, all 10 patients survived after 5 years of follow-up post-administration."

He continued, "Among the survivors, 9 remained relapse-free," and added, "In the investigator-initiated clinical trial of VT-Tri-A for acute myeloid leukemia patients, 71.4% of the treated patients survived relapse-free after 5 years of follow-up."

Researcher Oh emphasized, "The relapse-free survival rates for NK/T lymphoma and acute myeloid leukemia under existing treatments are only 26% and 11%, respectively," and "the majority of patients suffer from relapse."

He analyzed, "The therapies under development by VigenCell demonstrated excellent therapeutic effects by eliminating minimal residual disease and preventing relapse," and "this is a similar story to Green Cross Cell and Baxel Bio, which show excellent therapeutic effects as immune cell therapies."

Researcher Oh expressed expectations, saying, "Recently, companies developing immune cell therapies have been recognized with high market values," and "since Boryung Pharmaceutical has an excellent oncology sales organization, if the immune cell anticancer drug clinical trials succeed, significant synergy can be expected."